Related Experiment Videos
An in vivo assay for chemoattractant activity
Laboratory Investigation; a Journal of Technical Methods and Pathology
|September 1, 1985
Summary
Researchers developed an implantable device to study leukocyte chemoattraction. This novel tool effectively attracts and traps specific immune cells, enabling detailed analysis of cellular responses to various chemoattractants.
Area of Science:
- Biomedical Engineering
- Immunology
- Materials Science
Background:
- Leukocyte chemoattraction is crucial for immune responses.
- Studying cellular recruitment in vivo presents challenges.
- Existing methods lack the ability to quantify specific leukocyte subsets.
Purpose of the Study:
- To develop and validate an implantable device for studying leukocyte chemoattraction.
- To assess the device's capacity for controlled release of chemoattractant molecules.
- To analyze the distinct patterns of leukocyte accumulation induced by specific chemoattractants.
Main Methods:
- An implantable device was fabricated using Dacron fabric and ethylene vinyl acetate copolymer.
- The device was designed to release chemoattractant molecules over an extended period (≥18 days).
- Leukocyte accumulation within the Dacron fabric was analyzed after implantation and retrieval.
Main Results:
- The device successfully attracted and trapped specific leukocyte populations, including eosinophils, monocytes, neutrophils, and macrophages.
- Distinct cellular accumulation patterns were observed for different chemoattractant molecules (histamine, tuftsin, glycyl-histidyl-lysine).
- Maximal accumulation of neutrophils, monocytes, and macrophages/eosinophils occurred at specific postimplantation time points (days 1-2, 3-5, and 5-6, respectively).
Conclusions:
- The developed implantable device is effective for studying leukocyte chemoattraction in vivo.
- The device allows for the quantitative analysis of specific leukocyte recruitment patterns.
- The findings demonstrate the device's potential for investigating immune cell behavior and developing targeted therapies.